2-(piperidine-1-carbonyl)-5-iodopyridine | 1301214-67-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(piperidine-1-carbonyl)-5-iodopyridine
• 英文别名: 5-iodo-2-(piperidin-1-ylcarbonyl)pyridine；(5-iodopyridin-2-yl)-piperidin-1-ylmethanone
• CAS: 1301214-67-4
• 化学式: C₁₁H₁₃IN₂O
• 分子量: 316.142
• InChiKey: SNRSYHYLUHBGNR-UHFFFAOYSA-N

物化性质

• 沸点：
  419.1±30.0 °C(Predicted)
• 密度：
  1.665±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(piperidine-1-carbonyl)-5-iodopyridine 在 2,2,6,6-tetramethyl-piperidine-N-oxyl 、 potassium [¹⁸F]fluoride 、 potassium carbonate 、 间氯过氧苯甲酸 、 4,7,13,16,21,24-六氧-1,10-二氮双环[8.8.8]二十六烷 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成
  参考文献：
  名称：

  Development, Optimization, and Scope of the Radiosynthesis of 3/5-[¹⁸F]Fluoropyridines from Readily Prepared Aryl(pyridinyl) Iodonium Salts: The Importance of TEMPO and K₂CO₃

  摘要：

  A robust process for the radiosynthesis of 3/5-[F-18]fluoropyridines has been developed by radiofluorination of iodonium triflates using (KF)-F-18/(KCO3)-C-2/K-222 complex in the presence of TEMPO. Both electronically deficient and enriched iodonium salts were readily obtained from the corresponding 3/5-iodopyridines and afforded the corresponding 3/5-[F-18]fluoropyridines in 6-78% yields. The concentrations of K2CO3 and TEMPO were found to be crucial for the radiofluorination efficiency. The process was validated using two automated systems for the F-18-radiolabeling of 2-chloro and 2-carboxamido-5-fluoropyridines carried out in 10-20% yields.

  DOI：

  10.1021/acs.oprd.9b00021
• 作为产物：
  描述：

  (5-硝基吡啶-2-基)丙二酸二乙酯 在 palladium 10% on activated carbon 盐酸 、 硫酸 、 氢气 、 硝酸 、 sodium nitrite 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 21.42h， 生成 2-(piperidine-1-carbonyl)-5-iodopyridine
  参考文献：
  名称：

  N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors

  摘要：

  该发明提供了化合物I的化合物或其药用可接受的盐，其中R1、R2、R3和R4如本文所述；以及其药物组合物；以及在治疗受乙酰辅酶A羧化酶抑制调节的动物疾病、症状或紊乱中的使用。

  公开号：

  US20110111046A1

文献信息

• [EN] N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE N2-PYRAZOLOSPIROCÉTONE ACÉTYL-COA CARBOXYLASE
  申请人：PFIZER

  公开号：WO2011058473A1

  公开（公告）日：2011-05-19

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl- CoA carboxylase enzyme(s) in an animal.

  该发明提供了化合物(I)的结构或该化合物的药用盐，其中R1、R2、R3和R4如本文所述；以及其药物组合物；以及在治疗受乙酰辅酶A羧化酶抑制调节的动物疾病、症状或紊乱中的应用。
• Palladium-catalysed aminocarbonylation of diiodopyridines
  作者：Attila Takács、Georgina Márta Varga、Johanna Kardos、László Kollár

  DOI：10.1016/j.tet.2017.02.062

  日期：2017.4

  The aminocarbonylation of 2,5- and 2,3-diiodopyridine, as well as 2-chloro-3,4-diiodopyridine with carbon monoxide and various primary and secondary amines was carried out using palladium-catalysed aminocarbonylation. The formation of the products containing carboxamide and ketocarboxamide functionalities was accompanied by the formation of imides when ortho-diiodo compounds were used as substrates

  2，5-和2，3-二碘吡啶以及2-氯-3，4-二碘吡啶与一氧化碳以及各种伯胺和仲胺的氨基羰基化反应是通过钯催化的氨基羰基化反应进行的。当使用邻二碘代化合物作为底物时，形成含有羧酰胺和酮羧酰胺官能团的产物伴随着酰亚胺的形成。尽管有几种可能的反应途径，但通过适当地改变反应条件，大多数产物被合成为主要产物，具有合成目的的产率。
• N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
  申请人：Pfizer Inc.

  公开号：US08288405B2

  公开（公告）日：2012-10-16

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供公式(I)的化合物或其药学上可接受的盐，其中R1、R2、R3和R4如本文所述；其制备的药物组合物；以及在治疗动物中抑制乙酰辅酶A羧化酶酶的疾病、病状或障碍方面的用途。
• N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS
  申请人：Bagley Scott William

  公开号：US20120225900A1

  公开（公告）日：2012-09-06

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of said compound, wherein R 1 , R 2 , R 3 and R 4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供了式(I)的化合物或其药学上可接受的盐，其中R1、R2、R3和R4如本文所述；其药物组合物；以及在治疗动物中通过抑制乙酰辅酶A羧化酶酶的作用调节的疾病、症状或疾患中使用该化合物的方法。
• N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
  申请人：Pfizer Inc.

  公开号：US20130296319A1

  公开（公告）日：2013-11-07

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R 1 , R 2 , R 3 and R 4 are as described herein; pharmaceutical compositions thereof and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供一种式（I）的化合物或化合物的药学上可接受的盐，其中R1、R2、R3和R4如本文所述；以及其制成的药物组合物，并用于治疗动物体内受到乙酰辅酶A羧化酶酶抑制调节的疾病、病状或疾病。